WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

WINTON GROUP Ltd purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,880 shares of the biopharmaceutical company’s stock, valued at approximately $2,372,000.

A number of other large investors also recently modified their holdings of the company. iA Global Asset Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 979.5% in the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares during the period. SCS Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $34,784,000. Hsbc Holdings PLC increased its position in Alnylam Pharmaceuticals by 22.6% in the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after buying an additional 16,503 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $50,773,000. Finally, Keystone Investors PTE Ltd. bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $3,531,000. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on ALNY shares. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. TD Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Finally, Raymond James Financial upgraded shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target for the company in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $376.67.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $248.68 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The company has a 50-day simple moving average of $254.43 and a 200 day simple moving average of $288.99. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The company has a market capitalization of $33.28 billion, a PE ratio of 46.22 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the previous year, the company earned ($0.51) earnings per share. The company’s quarterly revenue was up 66.9% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).